Deok Ryun Kim

TL;DR: Shigella appears to be more ubiquitous in Asian impoverished populations than previously thought, and antibiotic-resistant strains of different species and serotypes have emerged.

TL;DR: This modified killed-whole-cell oral vaccine, compliant with WHO standards, is safe, provides protection against clinically significant cholera in an endemic setting, and can be used in children aged 1.0-4.9 years, who are at highest risk of developing cholERA in endemic settings.

TL;DR: Compared their incidences by using standardized methods from population-based studies in China, Indonesia, India, and Pakistan, which found that enteric fever in Asia is caused by Salmonella enterica serovar Typhi and not by S. Paratyphi A.

TL;DR: Sustained protection for 5 years at the level reported has not been noted previously with other oral cholera vaccines, and could assist policy makers formulate rational vaccination strategies to reduce overall cholERA burden in endemic settings.

TL;DR: The Vi vaccine was effective in young children and protected unvaccinated neighbors of Vi vaccinees, and the potential for combined direct and indirect protection by Vi vaccine should be considered in future deliberations about introducing this vaccine in areas where typhoid fever is endemic.